Wiseman R W, Fennell T R, Miller J A, Miller E C
Cancer Res. 1985 Jul;45(7):3096-105.
The identities of the adducts formed on reaction of the model electrophilic and carcinogenic esters 1'-acetoxysafrole or 1'-acetoxyestragole with deoxyguanosine in vitro and those formed in vivo in the hepatic DNA of 12-day-old male C57BL/6 X C3H/He F1 (hereafter called B6C3F1) mice treated with 1'-hydroxysafrole or 1'-acetoxysafrole were investigated further with more discriminating high-performance liquid chromatography systems than previously used. The adducts formed from the reactions of 1'-acetoxysafrole or 1'-acetoxyestragole are strictly analogous and are distinguished by the prefixes S and E, respectively. Five adducts, including S(E)-II identified by Phillips et al. (Cancer Res., 41: 176-186, 2664-2671, 1981) as N2-(trans-isosafrol-3'-yl)deoxyguanosine and the analogous isoestragole derivative, have been characterized from the reactions with each ester. Adducts S-I and E-I, tentatively identified by Phillips et al. as N2-(safrol-1'-yl)- or N2-(estragol-1'-yl)deoxyguanosine, were each resolved into a pair of diastereomers. The proposed structures for each diastereomer were confirmed by nuclear magnetic resonance and circular dichroism spectroscopy. Two new adducts, i.e., S(E)-V and S(E)-VI, were isolated from each reaction mixture. On the basis of their pKas, their loss of 3H from [8-3H]deoxyguanosine, their retention of 3H from [1',2'-3H]deoxyguanosine, and their nuclear magnetic resonance spectra, Adducts S-V and E-V were characterized as 8-(trans-isosafrol-3'-yl)- and 8-(trans-isoestragol-3'-yl)deoxyguanosine, respectively. Adducts S-VI and E-VI were characterized in a similar manner as 7-(trans-isosafrol-3'-yl)- and 7-(trans-isoestragol-3'-yl)guanine, respectively. Adducts S-III and E-III, minor components described in the earlier studies, were not observed in the present work. High-performance liquid chromatography of hydrolysates of the hepatic DNA of male 12-day-old B6C3F1 mice killed 9 h after a single dose (0.1 mumol/g body weight) of [2',3'-3H]-1'-hydroxysafrole showed that Adducts S-Ia, S-Ib, S-II, S-IV (identified by Phillips et al. as N6-(trans-isosafrol-3'-yl)deoxyadenosine), S-V, and S-VI were present at average levels of 3.5, 7.0, 24.4, 2.9, 1.2, and 3.6 pmol/mg DNA, respectively. Similar levels of these adducts were found in the hepatic DNA after administration of the same dose of [2',3'-3H]-1'-acetoxysafrole under identical conditions.
利用比以往更具分辨力的高效液相色谱系统,进一步研究了模型亲电致癌酯1'-乙酰氧基黄樟素或1'-乙酰氧基草蒿脑与脱氧鸟苷在体外反应形成的加合物,以及用1'-羟基黄樟素或1'-乙酰氧基黄樟素处理的12日龄雄性C57BL/6×C3H/He F1(以下简称B6C3F1)小鼠肝脏DNA在体内形成的加合物。由1'-乙酰氧基黄樟素或1'-乙酰氧基草蒿脑反应形成的加合物严格类似,分别以前缀S和E区分。包括菲利普斯等人(《癌症研究》,41:176 - 186,2664 - 2671,1981)鉴定为N2-(反式异黄樟素-3'-基)脱氧鸟苷的S(E)-II及其类似的异草蒿脑衍生物在内的五种加合物,已从与每种酯的反应中得到表征。菲利普斯等人初步鉴定为N2-(黄樟素-1'-基)-或N2-(草蒿脑-1'-基)脱氧鸟苷的加合物S-I和E-I,各自都被拆分为一对非对映异构体。通过核磁共振和圆二色光谱证实了每种非对映异构体的推测结构。从每个反应混合物中分离出两种新的加合物,即S(E)-V和S(E)-VI。根据它们的pKa值、从[8 - 3H]脱氧鸟苷中失去3H、从[1',2'-3H]脱氧鸟苷中保留3H以及它们的核磁共振光谱,加合物S-V和E-V分别被表征为8-(反式异黄樟素-3'-基)-和8-(反式异草蒿脑-3'-基)脱氧鸟苷。加合物S-VI和E-VI以类似方式分别被表征为7-(反式异黄樟素-3'-基)-和7-(反式异草蒿脑-3'-基)鸟嘌呤。早期研究中描述的次要成分加合物S-III和E-III,在本研究中未观察到。对单剂量(0.1μmol/g体重)[2',3'-3H]-1'-羟基黄樟素处理9小时后处死的12日龄雄性B6C3F1小鼠肝脏DNA水解产物进行的高效液相色谱分析表明,加合物S-Ia、S-Ib、S-II、S-IV(菲利普斯等人鉴定为N6-(反式异黄樟素-3'-基)脱氧腺苷)、S-V和S-VI的平均含量分别为3.5、7.0、24.4、2.9、1.2和3.6 pmol/mg DNA。在相同条件下给予相同剂量的[2',3'-3H]-1'-乙酰氧基黄樟素后,在肝脏DNA中发现了这些加合物的类似含量。